A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation

[1]  M. Hebert,et al.  Concomitant Tacrolimus and Micafungin Pharmacokinetics in Healthy Volunteers , 2005, Journal of clinical pharmacology.

[2]  M. Hebert,et al.  Concomitant Cyclosporine and Micafungin Pharmacokinetics in Healthy Volunteers , 2005, Journal of clinical pharmacology.

[3]  N. Chao,et al.  Pharmacokinetic and Maximum Tolerated Dose Study of Micafungin in Combination with Fluconazole versus Fluconazole Alone for Prophylaxis of Fungal Infections in Adult Patients Undergoing a Bone Marrow or Peripheral Stem Cell Transplant , 2005, Antimicrobial Agents and Chemotherapy.

[4]  D. Denning,et al.  Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  J. Lipton,et al.  Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  Thomas J Walsh,et al.  Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. , 2004, The New England journal of medicine.

[7]  A. Llanos-Cuentas,et al.  A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  Stephanie Green,et al.  Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria , 1992, Investigational New Drugs.

[9]  B. D. de Pauw,et al.  Voriconazole-a new therapeutic agent with an extended spectrum of antifungal activity. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[10]  B. Djulbegovic,et al.  Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Bow,et al.  Antifungal prophylaxis for severely neutropenic chemotherapy recipients , 2002, Cancer.

[12]  ohn,et al.  COMPARISON OF CASPOFUNGIN AND AMPHOTERICIN B FOR INVASIVE CANDIDIASIS , 2002 .

[13]  T. Walsh,et al.  FK-463 Fujisawa Pharmaceutical Co Ltd , 2000 .

[14]  S. Kohno,et al.  Efficacy of FK463, a (1,3)-β-d-Glucan Synthase Inhibitor, in Disseminated Azole-Resistant Candida albicans Infection in Mice , 2000, Antimicrobial Agents and Chemotherapy.

[15]  F. Ikeda,et al.  Efficacy of FK463, a New Lipopeptide Antifungal Agent, in Mouse Models of Disseminated Candidiasis and Aspergillosis , 2000, Antimicrobial Agents and Chemotherapy.

[16]  F. Ikeda,et al.  Efficacy of FK463, a New Lipopeptide Antifungal Agent, in Mouse Models of Pulmonary Aspergillosis , 2000, Antimicrobial Agents and Chemotherapy.

[17]  Koji Kawabata,et al.  In Vitro Activities of a New Lipopeptide Antifungal Agent, FK463, against a Variety of Clinically Important Fungi , 2000, Antimicrobial Agents and Chemotherapy.

[18]  L. Young,et al.  1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  R. Hay,et al.  Therapy of deep fungal infection in haematological malignancy. Working Party of the British Society for Antimicrobial Chemotherapy. , 1997, The Journal of antimicrobial chemotherapy.

[20]  W. Fibbe,et al.  Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  J. Enders,et al.  Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.